{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:32:17Z","timestamp":1773081137451,"version":"3.50.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tacrolimus is widely used as an immunosuppressant in the management of refractory nephrotic syndrome. Although effective, it may occasionally lead to rare but serious adverse effects such as posterior reversible leukoencephalopathy syndrome (PRES). PRES has traditionally been associated with hypertension and elevated drug concentrations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>In the present study, we describe the case of a 10-year-old Chinese girl who was diagnosed with steroid-resistant nephrotic syndrome (SRNS) and pathologically confirmed to have minimal change nephropathy. Following 40 days of full-dose glucocorticoid therapy with inadequate improvement in proteinuria, tacrolimus was initiated at 1.5\u2005mg twice daily (0.09\u2005mg\/kg\/day). Neurological symptoms, including headache and nausea, developed 18\u2005h after the first dose\u2014before steady-state drug levels were reached. Within 24\u2005h, hypertension emerged, and magnetic resonance imaging (MRI) revealed abnormal signals in the bilateral parietal cortical and subcortical regions, consistent with PRES. Tacrolimus was immediately discontinued, and the patient was treated with nifedipine, low-dose furosemide, and vitamin B6. Symptoms resolved within 48\u2005h, and blood pressure normalized. Immunosuppressive therapy was subsequently switched to mycophenolate mofetil (MMF). Follow-up brain MRI at three months demonstrated complete resolution of the detected abnormalities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tacrolimus-associated PRES may occur very early in treatment, even before stable drug concentrations are achieved. Vigilant clinical monitoring, prompt recognition of neurological symptoms, and timely intervention are critical to avoid long-term sequelae.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2026.1690215","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T06:43:19Z","timestamp":1769668999000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Tacrolimus-induced reversible posterior leukoencephalopathy syndrome in a child with nephrotic syndrome: a case report"],"prefix":"10.3389","volume":"14","author":[{"given":"Dengyan","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Pediatric Nephrology, Lanzhou University Second Hospital","place":["Lanzhou, China"]},{"name":"Department of Nephrology, Gansu Province Children\u2019s Hospital","place":["Lanzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Lanzhou University Second Hospital","place":["Lanzhou, China"]},{"name":"Department of Nephrology, Gansu Province Children\u2019s Hospital","place":["Lanzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Lanzhou University Second Hospital","place":["Lanzhou, China"]},{"name":"Department of Nephrology, Gansu Province Children\u2019s Hospital","place":["Lanzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nuclear Magnetic Resonance, Lanzhou University Second Hospital","place":["Lanzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Lanzhou University Second Hospital","place":["Lanzhou, China"]},{"name":"Department of Nephrology, Gansu Province Children\u2019s Hospital","place":["Lanzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Lanzhou University Second Hospital","place":["Lanzhou, China"]},{"name":"Department of Nephrology, Gansu Province Children\u2019s Hospital","place":["Lanzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S0140-6736(23)01051-6","article-title":"Childhood nephrotic syndrome","volume":"402","author":"Marina Vivarelli","year":"2023","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s00467-024-06605-0","article-title":"Prolonged remission after cyclophosphamide or tacrolimus treatment in childhood nephrotic syndrome: a cohort study","volume":"40","author":"Robinson","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ajem.2021.02.013","article-title":"Posterior reversible encephalopathy syndrome in the emergency department: a single center retrospective study","volume":"45","author":"Miller","year":"2021","journal-title":"Am J Emerg Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s40264-024-01398-5","article-title":"Tacrolimus-induced neurotoxicity after transplant: a literature review","volume":"47","author":"Verona","year":"2024","journal-title":"Drug Saf"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMra2114482","article-title":"Posterior reversible encephalopathy syndrome","volume":"388","author":"Geocadin","year":"2023","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e31568","DOI":"10.7759\/cureus.31568","article-title":"Angiotensin-converting enzyme inhibitor-induced angioedema following posterior reversible encephalopathy syndrome in a child:a case report","volume":"14","author":"Ichikawa","year":"2022","journal-title":"Cureus"},{"key":"B7","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.ejpn.2019.02.007","article-title":"Neurological complications in childhood nephrotic syndrome: a systematic review","volume":"23","author":"Stabouli","year":"2019","journal-title":"Eur J Paediatr Neurol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e30.31-e30.33","DOI":"10.1016\/S0272-6386(01)90016-2","article-title":"Reversible posterior leukoencephalopathy in a patient with minimal-change nephrotic syndrome","volume":"37","author":"Ikeda","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/practneurol-2021-003194","article-title":"Posterior reversible encephalopathy syndrome (PRES): diagnosis and management","volume":"22","author":"Triplett","year":"2022","journal-title":"Pract Neurol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s10072-018-3651-4","article-title":"Posterior reversible encephalopathy syndrome (PRES) and infection: a systematic review of the literature","volume":"40","author":"Racchiusa","year":"2019","journal-title":"Neurol Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/j.1399-0012.2009.01181.x","article-title":"Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor-related neurotoxicity after hematopoietic stem cell transplantation","volume":"24","author":"Yanagimachi","year":"2010","journal-title":"Clin Transplant"},{"key":"B12","doi-asserted-by":"publisher","first-page":"9156","DOI":"10.3748\/wjg.v19.i48.9156","article-title":"Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients","volume":"19","author":"Provenzani","year":"2013","journal-title":"World J Gastroenterol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10565-013-9263-0","article-title":"FK506 affects mitochondrial protein synthesis and oxygen consumption in human cells","volume":"29","author":"Palac\u00edn","year":"2013","journal-title":"Cell Biol Toxicol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1016\/j.transproceed.2008.08.033","article-title":"The production of reactive oxygen species in tacrolimus-treated glial cells","volume":"40","author":"Jin","year":"2008","journal-title":"Transplant Proc"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1007\/s00415-016-8377-8","article-title":"Posterior reversible encephalopathy syndrome","volume":"264","author":"Fischer","year":"2017","journal-title":"J Neurol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S1474-4422(15)00111-8","article-title":"Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions","volume":"14","author":"Fugate","year":"2015","journal-title":"Lancet Neurol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.mehy.2014.02.022","article-title":"Posterior reversible encephalopathy syndrome: the endothelial hypotheses","volume":"82","author":"Marra","year":"2014","journal-title":"Med Hypotheses"},{"key":"B18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2165\/11317550-000000000-00000","article-title":"Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part II","volume":"49","author":"Staatz","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s40620-020-00956-1","article-title":"Immunosuppression-related neurological disorders in kidney transplantation","volume":"34","author":"Faravelli","year":"2021","journal-title":"J Nephrol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1248\/bpb.23.1008","article-title":"Correlation between neurotoxic events and intracerebral concentration of tacrolimus in rats","volume":"23","author":"Sakamoto","year":"2000","journal-title":"Biol Pharm Bull"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cns.13207","article-title":"B vitamins in the nervous system: current knowledge of the biochemical modes of action and synergies of thiamine, pyridoxine, and cobalamin","author":"Calder\u00f3n-Ospina","year":"2019","journal-title":"CNS Neurosci Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2174\/1871527320666210902165739","article-title":"Neuroprotective role of the B vitamins in the modulation of the central glutamatergic neurotransmission","volume":"21","author":"Huang","year":"2021","journal-title":"CNS Neurol Disord - Drug Targ"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1139\/cjpp-2015-0098","article-title":"Antihypertensive and neuroprotective actions of pyridoxine and its derivatives","volume":"93","author":"Dakshinamurti","year":"2015","journal-title":"Can J Physiol Pharmacol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1690215\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T06:43:19Z","timestamp":1769668999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1690215\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":23,"alternative-id":["10.3389\/fped.2026.1690215"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1690215","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"article-number":"1690215"}}